Muvalaplin

DB21568InvestigationalSmall molecule

Muvalaplin is a small molecule drug. Muvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events).... Muvalaplin has a monoisotopic molecular weight of 710.4 Da.

Formula / weight: C₄₂H₅₄N₄O₆ · 710.916 g/mol (avg)
Code names: LY-3473329

Resolves to

Compound

UNIIHSU2KY4EFKCAS2565656-70-2ChEMBLCHEMBL4802585ChEBI758579PubChem155369486

Structure

InChIKeyBRLGERLDHZRETI-BGBFCPIGSA-NSMILES

[H][C@@]1(CCNC1)[C@H](CC1=CC(CN(CC2=CC(C[C@H](C(O)=O)[C@@]3([H])CCNC3)=CC=C2)CC2=CC(C[C@H](C(O)=O)[C@@]3([H])CCNC3)=CC=C2)=CC=C1)C(O)=O

Targets

P08519LPA

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Muvalaplin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account